Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T, López-Cadenas F, Aires-Mejía I, Caballero-Berrocal JC, Ortega R, Redondo AM, Sánchez-Guijo F, Muntión S, García-Martín L, Albarrán B, Alonso JM, Del Cañizo C, Hernández-Hernández Á, Díez-Campelo M. Jiménez-Solas T, et al. Among authors: redondo am. Br J Haematol. 2019 Oct;187(1):93-104. doi: 10.1111/bjh.16013. Epub 2019 Jun 6. Br J Haematol. 2019. PMID: 31172513 Free article. Clinical Trial.
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM, Pomares H, Vidal MJ, Pascual MJ, Quereda B, Sancho JM, Polo M, López J, Conde E, Jarque I, Alonso N, Ramírez MJ, Fernández P, Sayas MJ, Requena MJ, Salar A, González JD, González-Barca E, Arranz R, Caballero D, Martín A. Redondo AM, et al. Br J Haematol. 2014 Mar;164(5):668-74. doi: 10.1111/bjh.12676. Epub 2013 Nov 26. Br J Haematol. 2014. PMID: 24274082 Free article.
Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA. Sánchez-Guijo F, et al. Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19. Biol Blood Marrow Transplant. 2014. PMID: 24952358 Free article. Clinical Trial.
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Martín A, Redondo AM, Dlouhy I, Salar A, González-Barca E, Canales M, Montes-Moreno S, Ocio EM, López-Guillermo A, Caballero D; Spanish Group for Lymphomas and Autologous Bone Marrow (GELTAMO). Martín A, et al. Among authors: redondo am. Br J Haematol. 2016 Apr;173(2):245-52. doi: 10.1111/bjh.13945. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26847165 Free article. Clinical Trial.
HDAC8 overexpression in mesenchymal stromal cells from JAK2+ myeloproliferative neoplasms: a new therapeutic target?
Ramos TL, Sánchez-Abarca LI, Redondo A, Hernández-Hernández Á, Almeida AM, Puig N, Rodríguez C, Ortega R, Preciado S, Rico A, Muntión S, Porras JRG, Del Cañizo C, Sánchez-Guijo F. Ramos TL, et al. Among authors: redondo a. Oncotarget. 2017 Apr 25;8(17):28187-28202. doi: 10.18632/oncotarget.15969. Oncotarget. 2017. PMID: 28390197 Free PMC article.
Mesenchymal stromal cells (MSC) from JAK2+ myeloproliferative neoplasms differ from normal MSC and contribute to the maintenance of neoplastic hematopoiesis.
Ramos TL, Sánchez-Abarca LI, Rosón-Burgo B, Redondo A, Rico A, Preciado S, Ortega R, Rodríguez C, Muntión S, Hernández-Hernández Á, De Las Rivas J, González M, González Porras JR, Del Cañizo C, Sánchez-Guijo F. Ramos TL, et al. PLoS One. 2017 Aug 10;12(8):e0182470. doi: 10.1371/journal.pone.0182470. eCollection 2017. PLoS One. 2017. PMID: 28796790 Free PMC article.
Autologous mesenchymal stromal cells embedded in tricalcium phosphate for posterolateral spinal fusion: results of a prospective phase I/II clinical trial with long-term follow-up.
Blanco JF, Villarón EM, Pescador D, da Casa C, Gómez V, Redondo AM, López-Villar O, López-Parra M, Muntión S, Sánchez-Guijo F. Blanco JF, et al. Among authors: redondo am. Stem Cell Res Ther. 2019 Feb 22;10(1):63. doi: 10.1186/s13287-019-1166-4. Stem Cell Res Ther. 2019. PMID: 30795797 Free PMC article. Clinical Trial.
19 results